In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Henrik Andersen, former SVP and Head of Cell Therapy Technology Development at Bristol Myers Squibb, to explore how early planning, automation, and economic discipline can help scale the impact of cell therapies.

Henrik draws on his experience in both biologics and cell therapy to discuss how platform thinking, target product profiles, and cost-of-goods modelling can be applied earlier in development. Together, they reflect on the pitfalls of rushing to clinic without a viable manufacturing strategy, the shift in investor expectations, and why adapting lessons from biologics could help CGT companies avoid costly detours on the path to commercial success.

Connect with Henrik